ICE Regimen

Drug Overview

The ICE regimen is a powerful combination chemotherapy protocol used to treat relapsed or refractory blood cancers. “ICE” stands for its three components: Ifosfamide, Carboplatin, and Etoposide. Rather than a single drug, ICE is a carefully designed multi-agent combination where each drug attacks cancer cells through a different mechanism, maximizing the chance of achieving remission.

ICE is used primarily as a salvage regimen — meaning it is given when cancer returns or stops responding to first-line treatment. Its central goal is to shrink the disease enough to allow the patient to proceed to an autologous stem cell transplant, which offers the best chance of long-term remission.

• Regimen Name: ICE — Ifosfamide + Carboplatin + Etoposide
• US Brand Names: Ifex (ifosfamide), Paraplatin (carboplatin), VePesid (etoposide)
• Drug Class: Combination Cytotoxic Chemotherapy — Alkylating Agent + Platinum Compound + Topoisomerase II Inhibitor
• Route of Administration: Intravenous (IV) infusion
• FDA Approval Status: Each component drug is individually FDA-approved. ICE as a combination is a recognized standard-of-care salvage protocol used under established oncology guidelines; the combination does not carry a single unified FDA approval label.

What Is It and How Does It Work? (Mechanism of Action)

The strength of ICE comes from combining three drugs that destroy cancer cells through entirely different pathways, making it very difficult for cancer to escape or develop resistance.

Ifosfamide — DNA Cross-Linker: After activation in the liver, ifosfamide produces toxic metabolites that attach chemical bridges across both strands of the cancer cell’s DNA. This process — called cross-linking — physically prevents DNA from being copied, blocking cell division and forcing the cancer cell to die. A byproduct called acrolein accumulates in the bladder and causes bleeding, which is why ifosfamide is always administered alongside mesna (a bladder-protecting drug) and aggressive IV hydration.

Carboplatin — DNA Strand Disruptor: Carboplatin is a platinum-based agent that forms tight platinum-DNA bonds called adducts inside cancer cells. These bonds distort the DNA’s shape and activate the cell’s internal self-destruction alarm — a process called apoptosis. Carboplatin was specifically chosen over the older agent cisplatin because it causes far less kidney damage, making the ICE combination safer for more patients.

Etoposide — Topoisomerase II Inhibitor: Cancer cells depend on an enzyme called Topoisomerase II to untangle and repair their DNA during division. Etoposide locks this enzyme in a permanently broken state, causing irreparable DNA strand breaks. Without the ability to repair its own DNA, the cancer cell rapidly dies.

Together, these three agents strike cancer from three different angles simultaneously — a strategy that overwhelms even drug-resistant tumors.

FDA Approved Clinical Indications

Oncological Uses:

• Relapsed or refractory Diffuse Large B-Cell Lymphoma (DLBCL) — most common use; frequently combined with rituximab to form the R-ICE regimen
• Relapsed or refractory Hodgkin Lymphoma — used as second-line salvage before stem cell transplant
• Relapsed or refractory Follicular, Mantle Cell, and T-Cell Lymphoma
• Relapsed or refractory pediatric solid tumors — including neuroblastoma, Ewing sarcoma, and Wilms’ tumor

Non-Oncological Uses:

• There are no approved non-oncological indications for the ICE regimen.

Dosage and Administration Protocols

ICE is administered in repeating 21-day cycles, typically for two to three cycles before stem cell transplant eligibility is reassessed. Mesna must be co-administered with every ifosfamide dose, and G-CSF (granulocyte colony-stimulating factor) is started after each cycle to support white blood cell recovery.

Clinical Efficacy and Research Results

The ICE regimen was pioneered at Memorial Sloan Kettering Cancer Center and validated across multiple prospective clinical trials. In a landmark series of trials enrolling 222 patients with relapsed or refractory aggressive Non-Hodgkin Lymphoma, ICE produced an overall response rate (ORR) of 72%, with excellent stem cell mobilization — 86% of patients successfully collected the minimum required CD34+ cell dose for autologous transplant.

In a prospective outpatient study of 38 transplant-eligible patients with relapsed or refractory NHL and Hodgkin Disease, ICE achieved an ORR of 87% — with 37% reaching a complete response (CR) and 50% a partial response (PR). Among patients who achieved a CR after ICE followed by transplant, event-free survival was 88% at 11 months, compared to 45% for those achieving only a partial response — confirming that depth of remission directly determines long-term outcomes.

A larger outpatient series of 75 patients reported an ORR of 89%, with a 2-year overall survival of 65% for all lymphoma subtypes. The addition of rituximab to form R-ICE further improved outcomes in DLBCL. The CORAL study confirmed that R-ICE was non-inferior to R-DHAP in relapsed DLBCL, while a separate comparative analysis identified ICE as the best-performing salvage regimen among ICE, DHAP, and GDP in terms of overall response and transplant eligibility.

Safety Profile and Side Effects

Black Box Warning (Ifosfamide Component): Ifosfamide carries boxed warnings for severe myelosuppression (which can lead to fatal infections), CNS toxicity (including encephalopathy and death), nephrotoxicity (including renal failure), and hemorrhagic cystitis (bladder bleeding). Mesna and aggressive IV hydration are mandatory with every ifosfamide infusion.

Common Side Effects (>10%):

• Myelosuppression — Grade 3/4 neutropenia and thrombocytopenia occur in up to 72–80% of patients; G-CSF support is standard after every cycle
• Nausea and Vomiting — significant due to the high emetogenic potential of carboplatin and etoposide; prophylactic antiemetics are mandatory
• Alopecia (Hair Loss) — very common; typically fully reversible after treatment ends
• Fatigue — driven by anemia and systemic chemotherapy effects
• Hematuria (Blood in Urine) — monitor urine every 4 hours during ifosfamide infusion even with mesna in place

Serious Adverse Events:

• Ifosfamide-Induced Encephalopathy (IIE): Confusion, hallucinations, and seizures — stop ifosfamide immediately; administer methylene blue 50 mg IV every 4 hours until symptoms resolve
• Hemorrhagic Cystitis: Bladder bleeding due to acrolein; managed with additional mesna, increased IV fluids, and continuous bladder irrigation in severe cases
• Febrile Neutropenia: Life-threatening infection during the blood count nadir; initiate broad-spectrum antibiotics immediately without delay

Management Strategies:

• Monitor urine every 4 hours during ifosfamide; increase mesna and fluids at first sign of blood
• For encephalopathy: stop ifosfamide permanently; do not re-challenge; substitute cyclophosphamide if further alkylating therapy is needed
• For febrile neutropenia: start IV antibiotics immediately; do not wait for culture results

Connection to Stem Cell and Regenerative Medicine

ICE has one of the most direct connections to stem cell medicine of any chemotherapy regimen. It was deliberately designed with a dual purpose: to reduce tumor burden and to mobilize peripheral blood stem cells (PBSCs) for autologous transplant. Clinical data confirm that 86% of ICE-treated patients mobilize sufficient CD34+ cells without requiring additional mobilization strategies — a uniquely valuable feature. Ongoing research into the Pola-R-ICE combination (adding polatuzumab vedotin) has shown promising early data with improved complete remission rates before transplant in high-risk relapsed DLBCL patients, potentially setting a new standard for transplant-eligible salvage therapy.

Patient Management and Practical Recommendations

Pre-Treatment Tests:

• Complete blood count (CBC) with differential and platelet count
• Kidney function (eGFR/creatinine) and liver function tests (LFTs)
• Urinalysis — baseline blood in urine must be excluded before starting ifosfamide
• Pregnancy test for all women of childbearing age

Precautions During Treatment:

• Patients must drink at least 3 liters of fluid daily during and after ifosfamide infusion
• Urine must be tested every 4 hours while ifosfamide is running
• G-CSF must be started on Day 5 and continued until blood counts recover

Do’s and Don’ts:

• DO report any confusion, hallucinations, or unusual behavior immediately — these may signal encephalopathy
• DO urinate frequently during and after ifosfamide to help clear the bladder
• DO report any fever above 38°C (100.4°F) to your care team without delay
• DON’T breastfeed during or for 6 months after the last dose of ifosfamide
• DON’T miss scheduled blood tests — counts fall significantly after each cycle and require close monitoring
• DON’T take any new medications, supplements, or herbal products without consulting your oncologist first

Legal Disclaimer

The information in this guide is for educational purposes only and does not constitute medical advice, diagnosis, or a treatment recommendation. The ICE regimen involves potent cytotoxic agents that must only be administered under the direct supervision of a qualified oncologist in an appropriate clinical setting. Individual treatment decisions, including eligibility for this regimen and stem cell transplantation, must always be made in consultation with a licensed healthcare professional with full knowledge of the patient’s complete medical history. This content does not replace official prescribing information or professional medical judgment.